21 September 2018: According to Grand View Research, Inc., the worldwide non-vascular stents market is expected to attain USD 1.4 billion by 2025. Non-vascular stents are medical devices intended for relieving the strictures in urinary tract, airway tracts, gastrointestinal tract, and other. These stents are categorized into pulmonary (Airway) stents, gastrointestinal stents, urological stents, and other.
In January 2018, Elixir Medical Corporation introduced its new stent technology called DynamXTM at conference held in Denver. It is based on bioadaptive drug-eluting stent (BA-DES) platform. The DynamX composed of seventy-one microns thin cobalt-chromium DES that is covered with a biodegradable polymer covering which releases a Novolimus. The Novolimus is an anti-inflammatory and anti-proliferative that allows the vessel to continue arterial pulsatile motion as well as the Glagovian, an adaptive remodeling. These two conditions are vital to slowdown the development of disease. The thin biodegradable polymer covering is intended in such a way that it should get absorb in six months to restored adaptive remodeling and natural pulsatile motion of the artery.
In January 2018, Elixir Medical Corporation introduced its new stent technology called DynamXTM at conference held in Denver. It is based on bioadaptive drug-eluting stent (BA-DES) platform. The DynamX composed of seventy-one microns thin cobalt-chromium DES that is covered with a biodegradable polymer covering which releases a Novolimus. The Novolimus is an anti-inflammatory and anti-proliferative that allows the vessel to continue arterial pulsatile motion as well as the Glagovian, an adaptive remodeling. These two conditions are vital to slowdown the development of disease. The thin biodegradable polymer covering is intended in such a way that it should get absorb in six months to restored adaptive remodeling and natural pulsatile motion of the artery.
On 3 January 2018, Glaukos Corporation declared that it has applied for investigational device exemption (IDE) to the U.S. FDA to get an approval for studying its iStent infinite Trabecular Micro-Bypass System. It can be used in reducing intraocular pressure (IPO) in refectory glaucoma patients.
On February 27, 2018, Glaukos Corporation, announced the outcome related to its study of iStent infinite. According to study published in clinical ophthalmology, the implantation of one, two or three iStent Trabecular Micro-Bypass Stents achieved an average IOP reductions such as 30%, 37% and 43%, respectively, at thirty-six months postoperative.
Technological developments in stents such as radioactive and biodegradable stents, and improvements in stent designs, modification in material composition, and enhancement of stent placement techniques can propel the non-vascular stents market during the forecast period (2014 to 2025). In addition, growing adoption of minimally invasive surgeries and incidences of chronic diseases can boost the product demand.
Key players working in the market include Boston Scientific Corporation; C. R. Bard, Inc.; Synchron Med Inc.; HOBBS MEDICAL, INC; and CONMED Corporation.
In-Depth Research Report On Non-vascular Stents Market:
https://www.grandviewresearch.com/industry-analysis/non-vascular-stents-market
No comments:
Post a Comment